Restated Offer to Purchase, dated September 23, 2020 (the “Offer to Purchase”), and in the related Letter of Transmittal (the “Letter of Transmittal” which together with the Offer to Purchase collectively constitute the “Offer”), copies of which were filed as Exhibits (a)(1)(A) and (a)(1)(B), respectively, to Amendment No. 1 to the Tender Offer Statement on Schedule TO filed with the SEC on September 23, 2020. This Amendment is the final amendment and is being filed to report the results of the Offer. Capitalized terms not otherwise defined herein shall have the meanings ascribed to them in the Offer to Purchase.
The following information is furnished pursuant to Rule 13e-4(c)(4).
Item 11.
Item 11 is hereby amended and supplemented as follows:
1. The Offer expired at 11:59 p.m., New York time, on October 7, 2020.
2. 10,552,160 shares of common stock were validly tendered and not withdrawn prior to the expiration of the Offer. Because the Offer was oversubscribed, we will purchase a pro rata portion of the shares of common stock tendered by each stockholder.
3. The Company and Edenbrook will accept for payment up to 10,000,000 shares properly tendered and not properly withdrawn at a price of $2.15 per share, for a total purchase price of approximately $21.5 million in the aggregate. Of the shares accepted for payment, the Company severally, and not jointly, will accept for payment 5,000,000 shares for a total purchase price of approximately $10.8 million, and Edenbrook severally, and not jointly, will accept for payment 5,000,000 shares for a total purchase price of approximately $10.8 million. The shares to be accepted for payment by the Company and Edenbrook represent in the aggregate approximately 25.1% of the Company’s common stock issued and outstanding prior to consummation of the Offer.
The press release announcing the results of the Offer is attached hereto as Exhibit (a)(1)(H) and is incorporated herein by reference.